H. L. Davis

1.1k total citations
12 papers, 968 citations indexed

About

H. L. Davis is a scholar working on Immunology, Epidemiology and Molecular Biology. According to data from OpenAlex, H. L. Davis has authored 12 papers receiving a total of 968 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Immunology, 5 papers in Epidemiology and 4 papers in Molecular Biology. Recurrent topics in H. L. Davis's work include Immunotherapy and Immune Responses (8 papers), Immune Response and Inflammation (6 papers) and Virus-based gene therapy research (3 papers). H. L. Davis is often cited by papers focused on Immunotherapy and Immune Responses (8 papers), Immune Response and Inflammation (6 papers) and Virus-based gene therapy research (3 papers). H. L. Davis collaborates with scholars based in Canada, United States and Switzerland. H. L. Davis's co-authors include Michael J. McCluskie, A M Krieg, J. L. Gerin, R H Purcell, Simon C. Watkins, Curtis Cooper, Jonathan B. Angel, Isabelle Seguin, D. William Cameron and Tong Wu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Clinical Infectious Diseases.

In The Last Decade

H. L. Davis

12 papers receiving 928 citations

Peers

Countries citing papers authored by H. L. Davis

Since Specialization

Citations

This map shows the geographic impact of H. L. Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. L. Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. L. Davis more than expected).

Fields of papers citing papers by H. L. Davis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. L. Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. L. Davis. The network helps show where H. L. Davis may publish in the future.

Co-authorship network of co-authors of H. L. Davis

This figure shows the co-authorship network connecting the top 25 collaborators of H. L. Davis. A scholar is included among the top collaborators of H. L. Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. L. Davis. H. L. Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	CPG 7909 Adjuvant plus Hepatitis B Virus Vaccination in HIV‐Infected Adults Achieves Long‐Term Seroprotection for Up to 5 Years 2008 ·Clinical Infectious Diseases ·Curtis Cooper, Jonathan B. Angel, Isabelle Seguin, H. L. Davis, D. William Cameron	88
2	Combination of a new TLR9 agonist immunomodulator (CpG 7909) and paclitaxel for treatment of metastatic Lewis Lung Carcinoma (LLC) 2004 ·Journal of Clinical Oncology ·(unknown), (unknown), S. M. Sullivan, H. L. Davis, A M Krieg	5
3	Enhancing vaccines with immune stimulatory CpG DNA. 2001 ·PubMed ·A M Krieg, H. L. Davis	120
4	Adjuvant effects of CpG oligodeoxynucleotides on responses against T‐independent type 2 antigens 2001 ·Immunology ·Jiří Kovařík, Paola Bozzotti, Chantal Tougne, H. L. Davis, Paul‐Henri Lambert, (unknown), Claire‐Anne Siegrist	30
5	Immune-mediated destruction of transfected myocytes following DNA vaccination occurs via multiple mechanisms 2001 ·Gene Therapy ·(unknown), (unknown), (unknown), H. L. Davis	24
6	Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs 2001 ·Gene Therapy ·(unknown), Petar Lenert, Risini D. Weeratna, Michael J. McCluskie, Tong Wu, H. L. Davis, (unknown)	62
7	Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters 2001 ·Gene Therapy ·(unknown), Tong Wu, (unknown), (unknown), H. L. Davis	49
8	CpG motifs for optimization of DNA vaccines. 2000 ·PubMed ·H. L. Davis	17
9	CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. 1998 ·PubMed ·Michael J. McCluskie, H. L. Davis	227
10	Immune-mediated destruction of transfected muscle fibers after direct gene transfer with antigen-expressing plasmid DNA 1997 ·Gene Therapy ·H. L. Davis, (unknown), Simon C. Watkins	125
11	Mini-dystrophin gene transfer in mdx4cv diaphragm muscle fibers increases sarcolemmal stability 1997 ·Gene Therapy ·(unknown), (unknown), H. L. Davis, (unknown), George Dickson, B. J. Jasmin	40
12	DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. 1996 ·Proceedings of the National Academy of Sciences ·H. L. Davis, Michael J. McCluskie, J. L. Gerin, R H Purcell	181

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact